Fenbendazole-d3Fenbendazole-d3
MedChemExpress (MCE)
HY-B0413S
1228182-47-5
99.46%
4°C, protect from light *In solvent : -80°C, 6 months
-20°C, 1 month (protect from light)
Room temperature in continental US
may vary elsewhere.
Fenbendazole-d3 is a deuterium labeled Fenbendazole. Fenbendazole-d3 is a HIF-1α agonist and activates the HIF-1α-related GLUT1 pathway. Fenbendazole is an orally active benzimidazole anthelmintic agent, with a broad antiparasitic range. Fenbendazole is a microtubule destabilizing agent. Fenbendazole causes cell-cycle arrest and mitotic cell death, and has antitumor activity in mice xenografted with wild-type p53[1][2][3][4].
Fenbendazole-d3 (20 µM
for 48 h) reverses the inhibiting influence exerted by miR-143-5p on proliferation, colony-forming capacity, and migration[1]. Fenbendazole-d3 (10 µM
for 48 h) elevates the protein expression levels of HIF-1α and GLUT1[1].
| | | |
| | | | | |
[1]. Jia Xu, et al. miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway. Oncol Lett. 2022 May
23(5):147. [Content Brief]
[2]. Nilambra Dogra, et al. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 2018 Aug 9
8(1):11926. [Content Brief]
[3]. Hossein Aleyasin, et al. Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin. Antioxid Redox Signal. 2015 Jan 10
22(2):121-34. [Content Brief]
[4]. Qiwen Duan, et al. Fenbendazole as a potential anticancer drug. Anticancer Res. 2013 Feb
33(2):355-62. [Content Brief]